50 ms·

A (possible) solution to Covid-19

• danieltillett 7y ago
  I have posted this again as dang asked me to put it up again. Happy to answer questions about the idea, but I am most interested in find collaborators to make it happen ASAP.
  • grey-area 7y ago
    Have you posted it here? https://crowdfightcovid19.org/ https://crowdfightcovid19.org/
  • robomartin 7y ago
    I just sent your article to my contacts at the White House, Department of Defense, DARPA and a couple of other acronym agencies. I sent this to Director level people (or just under) at those agencies. No guarantees (they are all swamped). I hope they respond and put you in touch with the right people.
    • danieltillett 7y ago
      Thanks. This is the problem I have run into which is all the right people are so busy at the moment that they don’t have time to look at something like this from someone like me.
      • robomartin 7y ago
        Yes. I can confirm that your information got to one of my contacts at the White House. He replied saying he would distribute it to the right people. Your guess is as good as mine as to what happens from there. Even people within the White House have trouble penetrating through various layers due to just how busy everyone is (as well as security, etc.).
        • danieltillett 7y ago
          Thanks once again.
      • joncrane 7y ago
        Honestly at this point if you could get FOX News to pick up the story, the White House will know about it immediately.
        • danieltillett 7y ago
          I am sure you are right, but I don’t happen to know anyone from FOX News. If you do get in contact with me.
          • robomartin 7y ago
            I just forwarded your information and article to the producers for the top shows at Fox News. Let's see if they move on it and get in touch. I've also done the same for CNN producers. It'll be interesting to see who responds, if any. My standard advice still holds: Don't hold your breath. Sadly. All of these people are far more interested in ratings than things that matter.
  • mkl 7y ago
    A typo correction: In two places you have "overtime" instead of "over time".
    • danieltillett 7y ago
      Thanks - I will look for these.
• robocat 7y ago
  Another strain that might be less deadly: https://www.biorxiv.org/content/10.1101/2020.03.11.987222v1.full.pdf https://www.biorxiv.org/content/10.1101/2020.03.11.987222v1.... Also it is a paper from Singapore which should avoid the China negative bias.
  • danieltillett 7y ago
    This is exactly the sort of strain we want to be looking for all though we want a strain that doesn’t come from hospitalised patients. This deletion is still too pathogenic for our needs, but it does prove these deletion strains are out there. If we look we will find.
• elcomet 7y ago
  The best would be to find a mutation that cannot jump from human to human . Otherwise it could be dangerous if it mutates again to a more dangerous virus, even if not the original coronavirus (as you said we choose a mutation with a deletion).
  • danieltillett 7y ago
    No. A major part of the value would be the host to host transmission as it would get herd immunity into those people not directly given the virus. Only a transmissible virus strain can drive the pathogenic strains to extinction too. Large deletion mutations don’t back mutate in practice.
• AbrahamParangi 7y ago
  The author should test this idea on himself and demonstrate skin in the game.
  • danieltillett 7y ago
    I am more than happy to be exposed to an attenuated SARS-CoV-2 strain, but first we have to find one. My idea is how we can find one.
    • op00to 7y ago
      I think it would be pretty easy for you to find a strain. Start licking subway poles, then see what happens! Just kidding. Stay safe. ;)
      • _-___________-_ 7y ago
        If the virus managed to stay alive on a subway pole for very long, it's probably not very attenuated, no?
• dmichulke 7y ago
  I see two problems with this approach, both political / social: - No one will want to be the one "deploying" the attenuated strain in a human and then be responsible for some unforeseen death (even if it's just 1 in a billion). Utilitarianism is not widespread nor socially accepted. Even less so in politicians, who are quite risk averse. - There is no lobby supporting it. There's no $$ to be made and the "vaccine" is basically free.
  • FriedPickles 7y ago
    No one will want to be the one "deploying" the attenuated strain in a human and then be responsible for some unforeseen death (even if it's just 1 in a billion). Utilitarianism is not widespread nor socially accepted. Even less so in politicians, who are quite risk averse. I would give them more credit, especially in a situation where the status quo includes so many deaths. I was impressed with how readily most states licensed self-driving vehicles, knowing that there would certainly be deaths. Their rationality here likely came from seeing tens of thousands of people dying on the roads each year.
  • danieltillett 7y ago
    Lets solve this issues once we find the right attenuated strain. Personally I think these sort of social problems will be overcome once we compare with the alternative of sitting around waiting for a vaccine.
  • hdjrork 7y ago
    The flu vaccine (and others) kills more than 1 in a billion yet we still use it. And it would not be free, you still need to collect this strain, replicate it at massive scale and then distribute it.
• jka 7y ago
  This seems risky but worth consideration. Can you provide peer / concept review from virologists? A few items of feedback: - You could use a title that includes a distinct word to identify your proposed solution: "Using accentuated COVID-19 strains as a (possible) solution". This helps people to communicate and refer to the idea concisely. - The top three paragraphs may be known to your target audience; consider allowing the reader to get straight to your point. - It took me a while (certainly to the Q&A section) to grasp that attenuated virus strains are different from dangerous ones. Explaining this (perhaps in a brief sentence, then repeated and elaborated in a more detailed paragraph) near the top may also help. - Further references (especially peer review from respected authors) may help gain traction. Decision makers can be -- sensibly -- risk averse in global crises like these. Good luck!
  • danieltillett 7y ago
    I am a virologist - well I have published many papers in this area. I have a PhD in molecular microbiology and have been a tenured professor (I now work in the biotech sector). This is not intended to be a scientific paper, but a layman’s summary of the idea so non-technical people can understand the idea. It is not risky to go looking for a naturally attenuated virus. This is the first step that needs to happen.
    • jka 7y ago
      Thank you. I certainly get the sense from the article and your comments that you are well-informed. My suggestion is really one around building trust - it'd help to have others in the same scientific field confirm and/or question the approach.
      • danieltillett 7y ago
        This is exactly what I want to do. I want to collaborate with those in the position to go looking for one of these attenuated viruses.
        • 7y ago
• lpa22 7y ago
  Agreed that the risk:reward ratio here would be worth it. This sounds super promising. That being said, how is it known that having had the mutated strain provides immunity to the dangerous strain?
  • enchiridion 7y ago
    It probably won't be known at first, but we're talking a timescale of months to work out things like that. Things could be back to normal by the end of the year if we start now-ish. That is not blind hope either, it's just simple math.
  • danieltillett 7y ago
    The reason why it would provide immunity is all the structural proteins would be the same. To our immune system it would look like the same virus as the pathogenic strains. This is not really anything unusual and is exactly how viral live vaccines work. The vaccine for live polio and measles work exactly this way.
  • robocat 7y ago
    They know which parts of the RNA express the spike protein that our antibodies recognise. If the spike protein is not affected, then the virus should still be good for training our immune system to respond to.
• jbermudes 7y ago
  I'm glad people are realizing that all this social distancing is merely a pause button on the virus. Once we press play on society, exponential growth will happen again and we will have effectively rolled back the clock until we reach herd immunity through things like the OP's suggestion. At least this next time we'll hopefully have more PPE.
  • danieltillett 7y ago
    Exactly. There is also everyone in poor countries that is beyond the reach of expensive vaccines.
    • robocat 7y ago
      A country without other options might be more interested in the idea? I imagine that many first world countries would be too worried about the potential liabilities.
      • danieltillett 7y ago
        I suspect even the first world will be interested in options like this after a few more months of social isolation.
        • robocat 7y ago
          On second thoughts perhaps the idea wouldn’t work in countries that don’t have an effective lockdown. Could the infection wave of a less dangerous genotype overtake the number of infections of the more dangerous genotype before the population has been mostly infected already?
          • danieltillett 7y ago
            Yes if we act soon as we can spread the less dangerous version faster than the normal human-to-human spread of the dangerous version. For example if we were to send a postcard infected with the less dangerous version to 10 million people it would get out ahead of the dangerous version spreading normally.
• mirekrusin 7y ago
  Interesting, I wonder if this could explain to some extend different death ratios that are currently blamed on hospital capacity, age etc. - in other words, what if Italy has spread of more danerous mutation kind and Japan has spread of less dangerous one.
  • bede 7y ago
    The global sequencing effort makes this reasonably straightforward to study. While the prevalance of different strains does vary geographically, new international tranmission events occur so frequently that most places have a handful of circulating strains already [0] [0] https://nextstrain.org/ncov/europe https://nextstrain.org/ncov/europe
  • robocat 7y ago
    Trevor Bedford (who seems to know his shit) opines that different genetic variants are unlikely to have measurably different phenotypes/outcomes. See links here: https://news.ycombinator.com/item?id=22799096 https://news.ycombinator.com/item?id=22799096
• hilbertseries 7y ago
  You say > The reason why is immunity to respiratory viruses (like corona) doesn’t last long – 6 months to 2 years. I haven’t read anything like this before. It seems like you’re extrapolating from the flu vaccine, which doesn’t last because the flu mutates too quickly. Coronavirus mutate much slower and the thought is that we’ll likely only need one vaccine. Have we actually found any less deadly strains? My understanding is that there have been mutations, but all are small and as far as we can tell superficial. You would likely need to create such a mutation and then you’re back in vaccine trial territories, except dozens of labs that are experts on this have a head start.
  • danieltillett 7y ago
    We we have found less deadly strains (I link to one paper in the post that found one - still too deadly) and we have found strains with large (and small) deletions. What we haven’t done is go specifically looking for strains with exactly the properties we want (yet at least). There is no need to create any viral mutants in the lab (and all the difficulties this will involve), just use what is already out there in the community. We just need to go and look for them.
  • DanBC 7y ago
    https://www.nature.com/articles/d41586-020-00798-8 https://www.nature.com/articles/d41586-020-00798-8 > If humans do develop immunity, how long does it last? > That’s another big unknown. Immunity is short-lived for the coronaviruses that cause common colds; even people who have high levels of antibodies against these viruses can still become infected, says Stanley Perlman, a coronavirologist at the University of Iowa in Iowa City. > The evidence is more equivocal for the two other coronaviruses that have triggered epidemics: those that cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Perlman says his team has found that after people recover from MERS, their antibodies against the virus drop precipitously. He also says that his team has gathered data — not yet published — showing that SARS antibodies are still present in the body 15 years after infection. But it’s not clear whether this immune response is enough to prevent reinfection. “We don’t have good evidence of long-lasting immunity, but we also don’t have really good data from both SARS and MERS,” Perlman adds.
• papermachete 7y ago
  This is a repost since last time you asked how to reach Bill Gates.
  • dang 7y ago
    I invited danieltillett to repost https://news.ycombinator.com/item?id=22798626 https://news.ycombinator.com/item?id=22798626. My reason is to build up a body of community reactions to the idea, that can serve as a basis for deciding whether to promote it further. I don't know Bill Gates, but I do know some people inside YC who are hard at work on this problem, and maybe they know someone who knows someone, etc. If it's just a repetition of the previous thread, I'm sorry. Repetition isn't good and that wasn't my intention.
    • saagarjha 7y ago
      I know you often do so anyways, but perhaps these kinds of reposts deserve a comment explaining their circumstances.
      • dang 7y ago
        I don't think this would add much value, because it would attract attention away from submissions to the meta-business of their provenance on HN. I'm wary of adding bookkeeping facilities for that reason generally.
        • saagarjha 7y ago
          Fair enough; just thought I'd mention it because the lack of such bookkeeping seems to attract attention as well.
          • dang 7y ago
            It certainly does. It's a perennial sore spot, understandably. I just fear that trying to eliminate that pain would cause more pain.
    • 7y ago
• p1mrx 7y ago
  > it would be much better to just post a sample of the virus to everyone for example If COVID-19 is human malware, then this is a human software update.
  • oezi 7y ago
    At what probability of bricking during update would you stay on the old vulnerable version?
• Gupie 7y ago
  Isn't this just one of many ways to produce a vaccine, so won't it need the same long term trials for safety and effectiveness that any type of vaccine needs? Reducing this this time somehow is what I think is needed.
  • danieltillett 7y ago
    I address this in the post. The answer is no it is not just another vaccine approach.
    • Gupie 7y ago
      Do you mean this "virus would not be a vaccine from a regulatory perspective"? In that case it is just another vaccine approach, but one that you alledge falls outside the current regulations. Do you think the regulations need to change due to the emergency?
      • danieltillett 7y ago
        This is a question that really is unimportant at this point. What matters is what we can do today.
        • postingawayonhn 7y ago
          It's extremely important because it's a question a lot of people are going to be asking. You'll need a good answer as to why this approach should not be subject to similar regulations as vaccines otherwise this will go nowhere.
          • danieltillett 7y ago
            Is the FDA regulating the spread of the dangerous version? More seriously there is nothing for the FDA to regulate here. It is a natural virus spreading in a natural way.
• mbreese 7y ago
  From the comments on your site: > One thing is certain with the current situation is we need to take some risks if we are going to solve it quickly. Looking for quick answers in a crisis is really risky. There is a natural push to try to get things back to normal as soon as possible, but developing an attenuated vaccine (even with a potential strain already in existence), takes a lot of time and testing. I certainly agree that we should be trying to sequence every variation we can find in the wild, but even if everything works just right, it will take a lot of time. I haven’t followed enough of the reports, but how many strains have been identified thus far? Another issue is that even just getting the reagents to collect and passage the virus is difficult as they are all needed for clinical testing. So working with live (even attenuated) virus is very difficult at the moment. But this highlights a reason why it is so critical to study these topics when we aren’t in crisis mode. Much of the current vaccine work has been adapted from earlier SARS-CoV research. But this approach of finding a weakened strain (or generating one), is a good idea to be attempted in parallel. (I’m sure that someone is trying to passage the virus though a different host to attenuate it as we speak). The first step is to try and sequence as much as we can from the wild, but this has its own logistical difficulties. Hopefully there is a research study going on that is trying to collect as many samples as possible now, so that we can sequence later when things have calmed a bit (because there is likely going to be a second round). I don’t intend to sound so negative on this. I largely agree that this is one avenue that needs to be studied. And from your background, I know you understand these risks/concerns. I worry about the larger public though. My main concern is that this concept can be very risky, especially with an already scared public looking for quick answers. Seriously, the last thing we need is people intentionally trying to get infected in the hope of getting a less lethal strain. This isn’t a cowpox scenario. I guess my hesitation comes down to me not liking the idea of taking too many risks for the sake of doing it quick. That’s been known to come back and bite people.
  • danieltillett 7y ago
    Not doing something is very risky too. This is a problem with only hard choices.
• ziga 7y ago
  > More than 50% of the people infected with SARS-CoV-19 are asymptomatic (i.e. they have no illness). Note: asymptomatic at the time of testing. They may still develop symptoms over time. https://www.icelandreview.com/sci-tech/is-icelands-coronavirus-testing-showing-that-50-of-cases-have-no-symptoms/ https://www.icelandreview.com/sci-tech/is-icelands-coronavir... https://twitter.com/cmyeaton/status/1246196001775460358 https://twitter.com/cmyeaton/status/1246196001775460358
  • danieltillett 7y ago
    Yes this is true. For the purpose of my idea it doesn’t matter if the person is asymptomatic or they just have a mild case. What is important is the strain identified doesn’t put people in hospital.
    • andai 7y ago
      The key here is that the vulnerable population needs to tolerate it, too.
      • danieltillett 7y ago
        Technically they don’t provided we can get the herd immunity up to a decent level in the rest of the population. While it would be a good idea if the mutated strain was no more dangerous than a common cold coronavirus, we could drive the dangerous strains to extinction without having to infect the vulnerable.
        • jfoster 7y ago
          Very difficult to get herd immunity up to a decent enough level without putting the vulnerable portion of the population in great danger though. Most countries are approaching something like 0.1% or 0.2% of the population having been infected. Herd immunity requires 70% - 80% immunity. About 350x - 800x more than what's happened already. Also the whole thing presumes that immunity is lasting. Some of the data is showing that may not be the case.
• ImaCake 7y ago
  I want to argue that the flaw in this is with the ability to find any strain that consistently causes only minor symptoms. If you infect a whole group of people with Covid-19 then we would see a distribution of severity from no symptoms to lethal. This broad spectrum is really just it's statistical variance (whatever the underlying distribution really looks like). It is worth comparing this to things like SARS. The distribution of SARS symptoms would be pretty narrow - everyone gets really sick. So the variance for SARS is small compared to Covid-19. The same could be observed for influenza or rhinoviruses. The problem with a "milder" Covid-19 is that it might still have the same massive variance in symtpom severity. It might kill less people, but it would still be morally bankrupt to let it spread. In fact, it might be preferable to not reduce the mean severity, but just decrease the variance so it never gets nasty enough to kill without being immuno-compromised.
  • buboard 7y ago
    This paper argues on the basis of symptoms that there might be a milder strain that has dominated some countries vs others https://www.medrxiv.org/content/10.1101/2020.03.28.20036715v2 https://www.medrxiv.org/content/10.1101/2020.03.28.20036715v...
    • dboreham 7y ago
      There may be other explanations such as past use of vaccines for other diseases, that varies country to country.
      • ImaCake 7y ago
        Yes. Or just variations in our immune systems. Immune systems are incredibly complex systems. It is difficult to overstate just how complex and varied they are. And they differ between individuals to an amazing extent. If immunity is important to symptom severity, it may manifest as some weird correlation you might find in a cross-sectional study. Maybe gluten intolerance or a history of acid reflux will be a marker that lets you know what your risk of severe disease are.
• hb4ch 7y ago
  > We found, in our 788 confirmed COVID-19 patients, the decreased rate of severe/critical type, increased liver/kidney damage and a prolonged period of nuclear acid positivity, when compared with Wuhan. So how are we gonna deal this increased liver damage then, if we are actually gonna use this less pathogenic branch of the virus as a quasi-vaccine? Is there way to reengineer this virus so that it would be less kidney/liver damaging?
• user_50123890 7y ago
  I don't think the mutations are the reason for asymptomatic cases. Coronaviruses mutate very slowly. More likely, viral load, immune system strength, overall age and the genetics of the person infected are what determines if the infection is fought off before any symptoms are shown
  • user_50123890 7y ago
    And anyways, the harsh lockdowns currently implemented are basically forcing the virus to evolve into being asymptomatic. Currently, anyone with even mild flu-like symptoms stays home
    • mtnGoat 7y ago
      pardon my ignorance, but is that a good thing or a bad thing? (the first part)
  • danieltillett 7y ago
    I address this exact point in my post. This has nothing to do with the proposal.
  • nobrains 7y ago
    What is viral load, and doesn't it eventually become the same for everyone infected after some time during which the virus multiplies?
    • geomark 7y ago
      My understanding (not an expert) is that there is a difference depending how much of an initial dose of the virus you get. If it is very small then your immune system has more time to respond before the virus replicates to dangerously large numbers, whereas if your initial dose is large then you are starting with a large number of virus particles that replicate too fast for your immune system to respond.
      • pezo1919 7y ago
• sysbin 7y ago
  In theory the idea would work. People being cooperative enough is where I'm skeptical. I assume anyone in the high risk group would volunteer to receive the less-dangerous strain and when the incentive of lowering risk of death is obvious. I speculate young people wouldn't volunteer unless they have a health issue placing them in the high risk group.
  • logicchains 7y ago
    >I speculate young people wouldn't volunteer unless they have a health issue placing them in the high risk group. I suspect lots of young people would happily volunteer if it meant their life could return to normal. Heck, I'd bet even for the current strain, with a ~0.1% risk of death for young people, quite a few people would volunteer to get it if it meant they could get out of lockdown.
    • sysbin 7y ago
      I'm not disagreeing with that opinion. I just haven't observed young adults taking the lockdown seriously. I personally work from home (as one of the privileged few being a programmer) and when I do go outside I take social distancing serious. My health in general isn't great although I'm not old (early 30s) and which is why I don't leave my apartment much anymore. I live in a college area and young adults are still going over to each others apartments and without practicing social distancing when going out to buy groceries. I'm in Quebec for context. I've heard it isn't much different in the USA. Maybe the (possible) solution could work without young people on board.
      • logicchains 7y ago
        >I live in a college area and young adults are still going over to each others apartments and without practicing social distancing when going out to buy groceries. That's my point: the young adults don't want to comply with the social distancing, so if someone said "hey, if you let me infect you with this virus that has a 1/50,000 chance of killing you, you can no longer get/transmit the more dangerous strain so you don't have to social distance any more", a lot would take the offer.
• anonymouz 7y ago
  It seems the reason the vaccine will take so long (12-18months) to develop is because it needs to be tested for long-term safety which takes a trial with long-term monitoring. As this is essentially a sort of (active) vaccine, how do you propose ensuring it's long-term safety? It seems you'd run into essentially the same problem as with developing the vaccine.
  • riedel 7y ago
    It seems to me that the whole article describes to me an alternative way to find a vaccine . Maybe someone can enlighten me: aren't there vaccines that are simply rather harmless mutations/relatives of the virus but trigger the same immune reaction?
    • grey-area 7y ago
      Yes, there are https://en.m.wikipedia.org/wiki/Attenuated_vaccine https://en.m.wikipedia.org/wiki/Attenuated_vaccine
  • danieltillett 7y ago
    By doing an end run around the regulations. Actually even if you were to follow all the vaccine regulations by choice this would still be faster as it would have already been tested in human. Nature has run the trials for us.
    • anonymouz 7y ago
      I don't see the point of this. Nature has most certainly not established the long-term effects of this virus, seeing as it has only been spreading in humans for a short while. Skirting the regulations is pointless, because the important thing is the intent of the regulations. If it were just a problem with the regulations, we could also just change the regulations and give the untested vaccine. Plus, if you want to argue from a pure legal background, this approach would probably still run into trouble, as in most countries it would be highly illegal to infect people on purpose.
• conductr 7y ago
  Any back of envelope math on how much this "search" will cost? Does it require someone with Bill Gates sized bank account or are you mentioning him because you know he is specifically active in this area of philanthropy/very influential?
  • danieltillett 7y ago
    Yes. Less than a million dollars - I actually can afford to pay the whole thing myself. The only reason to get someone like Bill Gates involved it to get access to the samples and the required political capital to make it happen.
    • tim333 7y ago
      Cool. I hope you get it done.
• choeger 7y ago
  Stupid question: if you only search people with mild or even asymptomatic cases, how does that even tell you something about the virus? Should you not also search in (many) severe cases for the candidate, to exclude it from the list of dangerous virii?
  • danieltillett 7y ago
    There are no stupid questions, just stupid politicians. We are looking for an attenuated strain and that will be found in people with a mild case. We could sequence all cases, but we would exclude any strain that puts someone in hospital so it is a waste of resources to sequence viruses from people in hospital. From a practical perspective it is better to concentrate on people with only mild cases.
    • choeger 7y ago
      But honestly, if you only look into people with mild cases, how do you know the virus causes these mildness? If I pick 1k people with mild cases at random, I will find pretty much any strain that currently is in circulation. How do I know which strain is harmless?
      • danieltillett 7y ago
        You don’t, but what you are looking for is a virus with a largish deletion in an essential gene. You then go and look for anyone in contact with this person and check them and then expand out to the whole local area. If everyone infected with this strain has a mild illness they you have hit the jackpot. I do describe this in my blog post.
        • zxcmx 7y ago
          I think GP's point was that if you have a candidate it would also make sense to use sequences from the hospitalised to try and confirm your strain didn't put them there. Aka this being one mechanism by which you confirm it is only producing mild illness. There's a limited amount you can find out by asking because nobody knows what strain they had.
• buboard 7y ago
  Considering that we are now in a shutdown, and assuming that most symptomatic people do get tested and isolate themselves, doesnt that mean there is pressure for asymptomatic strains to evolve and keep spreading faster in the population anyway? they would be more likely to exist in the early epidemics, specifically south korea which aggressively quarantines people, but does not impose lockdowns, letting the asymptomatic spread
  • danieltillett 7y ago
    There is really no selection pressure on the current dangerous strain right now. If it was killing 50-60% of people infected then yes the selection pressure would be there, but at a death rate of 1.5%-2% there basically is very little selection pressure on the timescales we are interested in. It doesn’t really matter to us today if this virus eventually becomes less dangerous in the next 500 years. We need to speed things up a little.
    • buboard 7y ago
      > If it was killing 50-60% of people infected then yes the selection pressure would be there it isnt killing, but it's isolating them, preventing its spread
      • notahacker 7y ago
        That's already baked in to human responses to suspected COVID-19 though, and a chance mutation to a less lethal strain would be unlikely to change human responses to an outbreak in a way which benefited the virus' ability to spread.
        • buboard 7y ago
          i assume we re looking for asymptomatic people, they won't have quarantined themselves
    • postingawayonhn 7y ago
      Is there a significant difference between being dead and being isolated?
• elmolino89 7y ago
  Virus can be asymptomatic for a number of reasons. Host factors, such as age, (speculation) history of the previous coronavirus but not covid-19 infections, etc. Going after covid-19 genomes in a group of asymptomatic and symptomatic 70+ years old with sampling from different regions/countries may give us better data. Finding a mutated strain which never gives symptoms in old people from diverse locations, diet, health status etc. is the holy grail of this approach.
  • danieltillett 7y ago
    Yes. What we really want is a strain that has infected a whole lot of people and all of them have had a mild case.
    • londons_explore 7y ago
      You probably won't find that... You might find a strain where 99.9% of people get a mild case. Who is going to be the person to recommend deliberately spreading that strain to the world population, knowing that 0.1% of the world, 7 million people, will end up in a hospital and die? Sure, overall, fewer people might die, but the reality is whichever world leader makes that call has effectively just signed a death warrant for 7 million people. That isn't the way to get re-elected.
      • danieltillett 7y ago
        I think we can do better than 0.1% death rate. In principle there is no reason we can’t find a strain that is no more dangerous than the coronaviruses that cause the common cold. One thing is certain and that is unless we go out and look we won’t find anything.
        • Lordarminius 7y ago
          @danieltillett I could quickly put together a team focused on southern Nigeria and Ghana to find through word of mouth, medical records, contact tracing lists and social media, people who have experienced covid-19 symptoms and are likely to have had the disease. My team would also collect samples from people in the worst affected areas who are asymptomatic. In this way, we could collect data and enough samples to isolate a(?the) virus if any. Do you know any organisations that could provide funding and support for this ?
• ed_balls 7y ago
  I've been thinking about this a few days ago when I went into the wikipedia rabbit hole about vaccinations and inoculation. A few questions: - How about the dengue fever scenario? (Immunity to less pathogenic strain can cause more severe reaction with a different strain). Can we asses the risk somehow? > Apart from the time it will take to develop, trial, and mass produce a vaccine (12-18 months), it is unlikely that any vaccine will be practicable. The reason why is immunity to respiratory viruses (like corona) doesn’t last long – 6 months to 2 years Is there any proof that this is the case with this virus? Is is possible to do the infection outside the human body?
  • cjbprime 7y ago
    We just don't know. Either case (short immunity like the common cold, or permanent immunity) is possible.
    • ed_balls 7y ago
      It seem the permanent immunity is unlikely https://youtu.be/4EUZEtJHQhE?t=639 https://youtu.be/4EUZEtJHQhE?t=639
• bserfaty 7y ago
  Can't the attenuated strain mutate back to a strong dangerous one after we spread it? (Hope this isn't a stupid question)
  • ztjio 7y ago
    In theory any coronavirus could, including the 4 we consider absolutely harmless. In fact, with existing attenuated virus approaches that eventually becomes the problem, the "last mile" of this approach usually sees you needing a real vaccine to cap off the disease. Otherwise the virus kinda circulates around in a tight enough cycle that you see most if not all eventual mutations including dangerous ones that kill. Communities using attenuated virus vaccination approaches for Polio faced this in recent times, for example. And it becomes a problem in places where you can't get people to afford or accept the real vaccine. Anyway it's a tried/tested approach to solving a pathogen problem, so it's hardly some crazy idea this person has. They do point out the there will be specific types of mutations that are less likely to mutate back if you read the whole article.
    • danieltillett 7y ago
      The problem with polio back mutating is limited to one of the three strain in the live vaccine and is due to the mutations not being deletion mutations. The live polio vaccine was developed before people knew this and for regulatory reasons the problem has never been fixed. This problem is easy to avoid these days.
      • ztjio 7y ago
        I have no reason to believe you're wrong, I just wanted to point out that we (as a whole community of scientists etc.) can observe an entire range and lifecycle of this approach and that we're aware of the risks based not only on theory but on practice. Personally I see your proposal as a relatively worthy endeavor to consider.
  • Grue3 7y ago
    It's pretty hard to un-mutate a deleted gene sequence. It can mutate in a novel way to somehow cause more harm, but that won't be quick.
• gmanis 7y ago
  Daniel, Why can’t we use the virulent strain but in extremely small quantity? Like 1/1000 of the typical viral load?
  • cjbprime 7y ago
    That's covered by the post: because the person who received the small viral load will infect others and give them a large viral load.
    • gmanis 7y ago
      Thanks. How about a quarantine say 14 days after the small viral load delivery. Maybe we can do that to a subset of healthy young population so that they can go back to work without risking others? I don’t have much idea about either virology or molecular biology. Just curious.
  • deleted 7y ago
    [deleted]
• patall 7y ago
  A huge problem I see with this is that already circulating coronaviruses cause immunities as short as 3 months. While the SARS virus seems to cause much longer immunity (same for MERS), this may be linked to the strong symptomes that people have, thus may be due to a stronger immune reaction. Asymptomatic cases and people with mild symptoms may therefore be immune only for a short time. If this is the case, any herd immunity strategy will achieve not much but endanger many many people.
  • danieltillett 7y ago
    This is the exact problem my idea solves. Please take some time to read through the whole proposal again. I know this sound snarky, but yours is a really common response that has been addressed.
    • NyxWulf 7y ago
      I did read through your entire proposal, this is a legitimate question, and is not address in your proposal. It is definitely not the problem your proposal is aimed at solving. The question posed is would an attenuated virus create a much short immunity reducing efficacy of the overall approach. It seems like the only answer can be we don't know, we'd have to look at that.
      • danieltillett 7y ago
        Yes it could create a shorter immunity, but the idea is to use the attenuated strain to drive the dangerous strain to extinction. More fundamentally there are many questions that are unknown, but doing nothing until they are all answered it a choice that has a very high cost.
      • patall 7y ago
        Exactly. His whole proposal is based on the assumption that an attenuated strain imuunizes enough people long enough. This has been possible in other diseases. But for example not the common cold, and not only because many different virus belong to that category. So yes, I read your proposal. No, this is not addressed.
• beoh 7y ago
  This might be a naive question, but could this strain be created by some kind of gene editing?
  • danieltillett 7y ago
    Yes it could, but we wouldn’t know what edits to make. What this idea is using is nature to tell us what mutations make the virus less dangerous.
    • beoh 7y ago
      I see, thanks!
• 0k 7y ago
  Brilliant && simple. Why nobody is acting on it? Please correct spelling: ..I now work.. ..a number of papers.. Thank you, please spread the word (url).
  • danieltillett 7y ago
    No idea why nobody is acting on it - maybe nobody else has thought of it yet. While the idea of there being attenuated strains out there is nothing radical, the idea of using them is. Please everyone if you know someone you think might be able to help make this happen then spread the word. You are even welcome to steal the idea and claim it is your own :)
    • esfandia 7y ago
      Have you considered sending this as a letter to a medical journal? I know it's not a "scientific article" per se, but many journals have a section dedicated to letters. For example, CMAJ (Canadian Medical Association Journal) considers such letters, and right now they're fast-tracking anything COVID-related: https://www.cmaj.ca/ https://www.cmaj.ca/ Best of luck!
      • danieltillett 7y ago
        Yes I have, but the people I am trying to reach are not medical researchers, but people able to think outside the box.
• ignoramous 7y ago
  This is genuis if it could be put to work. Many possible vaccines for covid-19 are discussed in this paper [0] which is surprisingly accessible. There's a table [1] that depicts categorization of vaccine candidates and it does mention attenuated virus as a possible solution, the one in development by Codagenix and The Serum Institute of India [2] expected in the second-quarter of 2022. 2022 seems to be an eternity away, and the problems, as the paper points out, with attenuated vaccines are: 1. Requirement of a much wider phase 3 trial than other vaccine types. 2. Very time consuming to create such viral strains in the lab. There are overwhelming advantages working in its favour, though: 1. Human vaccines using the same platform exist for other diseases. 2. Existing infrastructure can be used to ramp up trials, approvals, manufacturing, and administration. The proposed solution by Dr. Daniel Tillett here makes sense because it turns those disadvantages on its head-- a substantial number of people might already have been infected with proven mild inflection and the strain(s) can be isolated at a much faster clip! [0] https://www.cell.com/immunity/fulltext/S1074-7613(20)30120-5 https://www.cell.com/immunity/fulltext/S1074-7613(20)30120-5 [1] https://www.cell.com/action/showFullTableHTML?isHtml=true&tableId=tbl1&pii=S1074-7613%2820%2930120-5 https://www.cell.com/action/showFullTableHTML?isHtml=true&ta... [2] https://seruminstitute.com/news.php https://seruminstitute.com/news.php
  • danieltillett 7y ago
    I am not sure about the genius part, but it can be done. While a search for an attenuated virus might fail (there might not be one out there yet), it at least won’t take long or cost much to look. Let's get started.
• new299 7y ago
  You make this statement: "The most important thing to note is that such a virus would not be a vaccine from a regulatory perspective." Can you provide any evidence to back up this statement? If you were to start intentionally infecting people with a (naturally) attenuated strain claiming that it will confer immunity I suspect authorities would request you get regulatory approval. If you're approach does require regulatory approval. What advantage does your approach have over those currently in developement? Some of them are just bits of the virus (mRNA that codes for the spike protein) packaged with a delivery mechanism [1]. It's a plausible approach, that has been tested in animal studies. There are a number of other, similarly plausible vaccines entering human trials. It is however deemed to be too high risk to just start giving the vaccine to large numbers of people. So the vaccine will have to go through (an accelerated) trial process. It will then likely be given to at risk groups (health care professionals), before becoming widely available. Most experts expect this to take at least 16 months (which would be a world record). Your approach would have the same issues as are present with any other vaccine. If regulatory authorities are willing to skip trials for your approach, then the same should apply to other vaccines under development. [1] https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19 https://www.modernatx.com/modernas-work-potential-vaccine-ag...
  • danieltillett 7y ago
    You are looking at this from the wrong perspective. If people start spreading this attenuated strain around on their own what are the regulatory agencies going to do? Even if you wanted to go down the regulatory pathway for some reason it still has a number of advantages over other approaches. 1. We would know it is safe in humans before we began. 2. We would know what mutations make the virus less pathogenic. 3. Once used it would drive the pathogenic strains to extinction. 4. It will be work in poor countries that can’t afford or distribute a conventional vaccine. 5. It will infect and protect those that are not deliberately infected through contact with others.
    • new299 7y ago
      > What are regulatory agencies going to to do? If you were to start doing this without regulatory approval, the most likely outcomes seems that you’d be arrested [1]. Do you have anything that suggests otherwise? > 1. We would know it is safe in humans before we began. The regulatory requirements for “knowing it is safe in humans” are currently quite high. As things stand, I would expect trials to be required. Can you provide any evidence to suggest trials wouldn’t be required? You want to know how the vaccine effects individuals with pre-existing conditions etc. etc. And, as there’s always some risk, you want to be sure that the vaccine is effective. > 2. We would know what mutations make the virus less pathogenic. Large scale sequencing of the virus, in individuals and populations will be interesting. Being able to link this patient outcomes is also interesting. And might help in vaccine development. It would be interesting to have a large dataset of viral sequences from asymptomatic individuals. Can we see clear differences between asymptomatic and symptomatic individuals? This would be an interesting dataset, but I’m not sure that the results would be as clear as “look this deletion exists in a sub-population of asymptomatic individuals”. Would be a cool dataset and an interesting project though. There seems to be a lot of NGS data [2] available. This might be a suitable starting point for such a project. > 4. It will be work in poor countries that can’t afford or distribute a conventional vaccine. If a vaccine is available, then I suspect there will be sufficient international support to make it widely available. Having an active outbreak anywhere in the world would likely be deemed an unacceptable risk, given the potential for further mutation. [1] https://www.theverge.com/2020/3/26/21195236/fbi-doj-arrest-fake-coronavirus-vaccine-cure-covid-19-keith-middlebrook https://www.theverge.com/2020/3/26/21195236/fbi-doj-arrest-f... [2] https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/ https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/
• nabla9 7y ago
  There are several pre-clinical studies with live attenuated viral vectors and replicating viral vectors going on against SARS-CoV-2. https://www.who.int/blueprint/priority-diseases/key-action/list-of-candidate-vaccines-developed-against-sars.pdf?ua=1 https://www.who.int/blueprint/priority-diseases/key-action/l... Developing attenuated-virus vaccines is by screening serially propagated SARS-CoV-2 for reduced pathogenity has also been suggested already. 1. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines https://www.nature.com/articles/s41541-020-0170-0 https://www.nature.com/articles/s41541-020-0170-0 2. Regla-Nava, J. A. et al. Severe acute respiratory syndrome coronaviruses with mutations in the E protein are attenuated and promising vaccine candidates. J. Virol. 89, 3870–3887 (2015). https://www.ncbi.nlm.nih.gov/pubmed/25609816/ https://www.ncbi.nlm.nih.gov/pubmed/25609816/ Authors idea of spreading the attenuated virus is based on the idea that if the immediate COVID-19 disease can be avoided, increasing viral load in population is smaller risk. I think that's the weak point. If the vaccine is developed and the virus establishes itself in the population, the number of people getting infected will be lower overall and less people will get severe disease due to natural immunity + vaccine. ps. > appears to be killing between 1% to 3.5% of the people it infects Author is confusing case fatality rate (CFR) with infection fatality rate (IFR). Infection fatality ratio seems to be something like 0.6% according to recent estimates. IFR estimates seem to go down over time.
  • travisporter 7y ago
    I think you mean infection fatality rate. You gave me a heart attack for a second as I wiki’d it.
  • danieltillett 7y ago
    This is not a proposal for a live attenuated vaccine. These numbers on the death rate are not mine, but what has been reported in the scientific literature. Probably the best numbers come from South Korea where they have done a pretty good job of tracking down everyone infected. There the fatality rate is around 1.8%. Even if the true death rate is 0.6% that still means the deaths of nearly 50 million people worldwide.
    • 7y ago
• ubercow13 7y ago
  How would you allow the harmless strain to spread without also spreading the deadly strain? If you relax or reverse social distancing, wouldn't the deadly strain also have a chance to spread widely again? It seems like you'd need to manually administer this strain to millions of people, or have very carefully administered 'contagion parties' where everyone is pre-screened for the deadly strain, while everyone else keeps social distancing.
  • sfj 7y ago
    > It seems like you'd need to manually administer this strain to millions of people. Yes, but this doesn't seem too hard. Just have some infected people spit in a cup, and mix it into large vats of raspberry jam and people can then just spread it on their toast on one morning.
    • hanspeter 7y ago
      > Currently, there is no evidence to support transmission of COVID-19 by food. https://www.fda.gov/food/food-safety-during-emergencies/food-safety-and-coronavirus-disease-2019-covid-19 https://www.fda.gov/food/food-safety-during-emergencies/food...
      • sfj 7y ago
        What does food that regulated by the FDA have to do with this?
  • throwaway_pdp09 7y ago
    > you'd need to manually administer this strain to millions of people Yes. And how would that compare to the various trillions in stimulus to keep a choking world economy afloat, never mind the deaths that could be avoided? I don't understand posts like this, they say "if we had a good solution, how could we possibly use it?"
    • ubercow13 7y ago
      I think you’re reading too much into my post, I was just wondering how to safely carry out this idea. One reason I was wondering is that manually administering the virus to people seems more akin to a vaccine in nature.
• tomohawk 7y ago
  Apparently China has at least one hospital full of asymptomatics. https://www.straitstimes.com/asia/east-asia/mystery-of-long-term-patients-confounds-wuhan-doctors https://www.straitstimes.com/asia/east-asia/mystery-of-long-...
• ajnin 7y ago
  The idea of voluntarily infecting the entirety of the population with a virus to prevent economic downturn seems a very dangerous idea to me. The purpose of society is to ensure the well-being of the people. It is not economic growth. Furthermore, I see a few problems with that idea : - it seems very hard to create a truly harmless virus. Viruses still destroy cells to replicate, they cause immune system response, inflammation, what would happen to weak or immunocompromised people ? - if immunity through vaccines lasts 6 to 24 months, why wouldn't this be the case here too ? You'd still need to develop a vaccine or keep infecting people with new strains of this virus - why would the deadlier strain disappear ? Unless you also engineer the mild strain to be much more infectious, both strains would still spread equally in the population. Presumably the milder strain would be less symptomatic so it would in fact spread less - it's not demonstrated in what way economic downturn would be more harmful in the end. Economy is a means not an end.
  • DCKing 7y ago
    > The purpose of society is to ensure the well-being of the people. It is not economic growth. "Growth" is not the issue, but economic prosperity and stability is immensely important with respect to the well-being of the people. Economic downturns also reliably cost lives in a huge amount of different ways. I'll consider this idea to be pretty whack until people smarter than me think it's a good idea. But I hope we can come to terms that it's worth discussing taking some health risks to limit economic downturns. "People's lives" vs "the economy" is a false dichotomy.
  • uk_programmer 7y ago
    The reason why you need economic growth is to ensure the well being of your people, you talk about them as they are not interlinked when they very much are. Other countries (some that may not care about the well being of their citizens) will be quite happy to take your place hierarchy and exert their influence over the world as they see fit, which may well be to the detriment to your nation (and nation is comprised of its people).
• _-___________-_ 7y ago
  > SARS-CoV-2 (the virus that causes COVID-19) appears to be killing between 1% to 3.5% of the people it infects The article that this text links to discusses case fatality rate, which is not the percentage of people the virus infects that die. This is a fundamental and very important difference, especially given that you later note the percentage of asymptomatic people.
  • danieltillett 7y ago
    Nobody knows the true asymptomatic rate, but even if it is 5o% the number of people that will be killed is massive. Let’s not get caught up on the final death rate and let’s look at what we can do right now.
    • _-___________-_ 7y ago
      The OP literally opens with a misinterpreted statistic. It links to an article about CFR and claims that the values are IFR instead of CFR. This is not "getting caught up on something", I'm pointing out a fundamental error. Most serious estimates of IFR are between 0.1 and 0.6%. The OP should be edited to either correctly state that COVID-19 kills between 1 and 3.5% of identified cases, or be updated to use numbers that are not misleading.
      • danieltillett 7y ago
        These IFR numbers you quote are also incorrect as there are many people infected who have not yet had time to die. The best estimate probably comes from South Korea (they seem to be picking up nearly all cases with their massive contact tracking and testing) where the death rate is at 1.8% and trending higher.
        • _-___________-_ 7y ago
          Then why not link to a study about the IFR in South Korea? My point is that the claim you make about the percentage of people who are infected that die is not supported at all by the article that the claim links to, which only discusses the percentage of confirmed cases that die.
• rmu09 7y ago
  The results of a study in austria with 1500 randomly selected citizens have just been published, just 5 have been found to be currently infected with SARS-CoV2. The conclusion is that the prevalence of asymptomatic cases is about 0,32%, CL95 is 0,12-0,76%. Link (in german): https://www.sora.at/nc/news-presse/news/news-einzelansicht/news/covid-19-praevalenz-1006.html https://www.sora.at/nc/news-presse/news/news-einzelansicht/n...
  • danieltillett 7y ago
    We are really more interested in mild cases, not asymptomatic cases. The evidence seems to be that most asymptomatic infections go on to show some symptoms at a later date.
    • rmu09 7y ago
      They didn't really say asymptomatic or mild case, but presumably people with (strong) symptoms would have gotten a test and already be in the official statistics. The next study that is currently being prepared will include antibody-tests, but it seems logistics and which test to use is not a trivial matter.
  • FiberBundle 7y ago
    This goes contrary to what other studies have found. In the Stockholm metropolitan area they found that 2.5% percent of the population was infected [1]. In in a community in Germany, which was the epicenter of the outbreak for a time, they found that 15% of the population tested positive for antibodies [2]. In Iceland they found that 88-93% of the infections are undetected [3]. [1] https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/april/resultat-fran-undersokning-av-forekomsten-av-covid-19-i-region-stockholm/ https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhets... [2] https://www.land.nrw/sites/default/files/asset/document/zwischenergebnis_covid19_case_study_gangelt_0.pdf https://www.land.nrw/sites/default/files/asset/document/zwis... [3] http://www.igmchicago.org/wp-content/uploads/2020/04/Covid_Iceland_v10.pdfhttp://www.igmchicago.org/wp-content/uploads/2020/04/Covid_Iceland_v10.pdf http://www.igmchicago.org/wp-content/uploads/2020/04/Covid_I...
• weakstrain 7y ago
  The author is thinking that reversing a deleted zone mutation is hard, but it could be that a simple mutation of the weak strain make it deadly, so my question is: can you guarantee that a new mutation is not going to make this strain deadly?, also the more people with the new strain of the virus, the more the bad mutation could happen. So I suggest looking for a strain for which we have a mean of killing the virus, that is a weak virus for which we have a general vaccine for expected mutations, if that is possible.
  • dpratt71 7y ago
    There are no guarantees in life, but the reason we don't have global pandemics constantly is that mutations that make a virus as dangerous as SARS-Cov-2 are quite rare.
    • jfoster 7y ago
      There actually has been quite a lot of pandemics over the past 100 or so years. Covid-19 has yet to eclipse at least 3 of them. (1918, 1957, 1968)
• dongping 7y ago
  I'm not qualified to assess the risk, but if the there's indeed ADE (antibody dependent enhancement),[1][2] people once infected with a milder strain may suffer from more severe symptom from the deadlier strains, thus killing more people in the end. I'm wondering how we may rule out this worst case scenario. [1] Is COVID-19 receiving ADE from other coronaviruses? https://www.sciencedirect.com/science/article/pii/S1286457920300344 https://www.sciencedirect.com/science/article/pii/S128645792... [2] New blood tests for antibodies could show true scale of coronavirus pandemic https://www.sciencemag.org/news/2020/03/new-blood-tests-antibodies-could-show-true-scale-coronavirus-pandemic https://www.sciencemag.org/news/2020/03/new-blood-tests-anti...
  • danieltillett 7y ago
    ADE is more a problem for the vaccine approaches. It is one reason we may never have a vaccine for this disease. Hard to rule out worst case scenarios, we just have to work with what we have and make hard choices.
    • twomoretime 7y ago
      >ADE is more a problem for the vaccine approaches. It is one reason we may never have a vaccine for this disease. This is at least partly why there are no SARS/MERS vaccines. There's a paper I'll try to dig up where 4-8 (can't remember) modified vaccine candidates were tested in multiple animal species, and in each case except one, immunity was conferred but exposure to the virus lead to a dangerous autoimmune response which destroyed lung tissue.
      • wbl 7y ago
        That's not ADE as I understand it. ADE is where the virus gets grabbed more easily by cells thanks to the antibodies on it proving handles.
        • twomoretime 7y ago
          Well yes, because of ADE the normal antibodies released by the immune response immediately increase the replication rate so you have a far more severe reaction upon infection than you would otherwise. That's why I'm waiting for confirmation of immunity. So far I've only seen increasing numbers of reports of reinfection but that may just be faulty testing.
• deleted 7y ago
  [deleted]
• losvedir 7y ago
  How does the Iceland data suggest the hypotheses that 1) an attenuated strain exists in the wild and 2) it provides immunity to the worse strain? It's asserted in the post, but I don't see it. It seems likely to me their experience isn't any different from any other country's, and they're just testing more. The idea in the post is obviously a good one if it can be done, it's just that it seems like a generic idea that should be considered for any viral pandemic, which makes me wonder why it's not already an approach people are working on.
  • danieltillett 7y ago
    It doesn’t which is why I never claimed it did??? As for why people aren’t working on this idea I don’t know. Maybe someone is and they will send me an email and I can update my post. I would certainly be extremely happy with this outcome.
    • losvedir 7y ago
      I was responding to this from your blog post: > This data suggests a simple and testable hypothesis – there are natural strains of SARS-CoV-2 in the world that have mutated to be non-pathogenic (asymptomatic), but are still infective and will provide immunity to the more pathogenic (deadly) strains. From the structure of the post it sounded like "this data" referred to Iceland plus the Wuhan study. If you only meant the Wuhan study then apologies for misunderstanding.
      • danieltillett 7y ago
        Yes both. The Icelandic data suggests there is genetic diversity in SARS-CoV-2 and the Wuhan data suggests there are strains that are less pathogenic. There is also a Singapore study that has identified strains with large gene deletions, but I haven’t yet updated the post to include it [0]. 0. https://www.biorxiv.org/content/10.1101/2020.03.11.987222v1.full.pdf https://www.biorxiv.org/content/10.1101/2020.03.11.987222v1....
        • 7y ago
• hebrox 7y ago
  Could we already start with this? There are almost no deaths in young people, so how about we send the youth to a Corona Summer Camp for a week or 3? https://www.worldometers.info/coronavirus/coronavirus-age-sex-demographics/ https://www.worldometers.info/coronavirus/coronavirus-age-se...
  • rvnx 7y ago
    How much % of young people end up in ICUs or hospital ? The numbers are always elusive about that.
    • hebrox 7y ago
      According to CDC : Age group (yrs) 0–19 (123 cases) Hospitalization 1.6–2.5 ICU admission 0 Case-fatality 0 https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm
      • rvnx 7y ago
        Thanks a lot!
  • DanBC 7y ago
    relying on numbers from February feels sub-optimal, especially when they're entirely using numbers from one country, not many countries.
    • hebrox 7y ago
      US numbers in March: https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e3.htm#F1_down https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e3.htm#F1_down
• yters 7y ago
  South Korea somehow avoided the whole lockdown approach.
  • danieltillett 7y ago
    Yes, but that train has left the station in most other countries.
  • Igelau 7y ago
    Can we confidently say what has or hasn't been avoided by anyone? It seems a little early to be counting our chickens.
  • cmoscoso 7y ago
    I heard that most of the elderly in South Korea already live in isolation.
• TuringNYC 7y ago
  Dear @danieltillett - Thanks for the thoughtful piece. You noted on your post "live attenuated (oral) polio vaccine" but later wrote "Apart from the time it will take to develop, trial, and mass produce a vaccine (12-18 months), it is unlikely that any vaccine will be practicable." So how do you imagine this solution being administered if not as a vaccine? Is the solution a Pox Party (https://en.wikipedia.org/wiki/Pox_party https://en.wikipedia.org/wiki/Pox_party) with someone verified to have the harmless strain?
  • danieltillett 7y ago
    A pox party would work. Given the strain will be infectious like the dangerous strains it is not going to be too hard to spread it around. You can look at it from the other perspective - once identified it would be impossible to stop people spreading it around on their own. Let’s say one of you friends got infected with this “safe” strain you would quickly head over to their home for a cup of tea and a good chat.
    • barbs 7y ago
      Much like the dangerous virus can mutate to a less harmful version of itself, isn't there a risk that the benign version could mutate back to a (more) dangerous form if spread this way?
      • danieltillett 7y ago
        Not if you select a strain with the right mutation.
    • TuringNYC 7y ago
      Thanks for the thoughts @danieltillett. I'm sorry you are not getting more traction on the idea. I'd sign up for this if I had this! IANAL but I did run an infection detection medical diagnostics startup for 3yrs that I co-founded. Since we're on HN, perhaps here is how you might get traction (note, i'm just throwing this out move-fast-and-break-things-style for the sake of brainstorming): 1. Form a company, announce the idea bigtime! (Incorporate overseas for liability protection?) 2. Sell a sequencing service that tells you the strain you have -- offer no medical advice. Not a diagnostic for medical purposes, more like 23&me (does this get around regs?) 3. Offer a free matching service to find locals with the strain, perhaps with an app to validate their strain, etc. (some incentive for the customer?) Note this isn't legal advice, but it would be awesome if someone with the correct background could provide feedback on this approach. As for my startup, we sold overseas in easier reg jurisdictions -- we were never able to break into the US market.
• efavdb 7y ago
  Pooling could be used to more rapidly test the asymptomatic population: https://github.com/EFavDB/pooling https://github.com/EFavDB/pooling
  • danieltillett 7y ago
    Even better than pooling is griding [0]. 0.https://twitter.com/rwade300/status/1247340350076628992 https://twitter.com/rwade300/status/1247340350076628992
    • sampo 7y ago
      If B2 and D4 are positive, then in the marginals B,D,2,4 will show positive, but you don't know which of B2, B4, D2, D4 are positive.
      • danieltillett 7y ago
        Yes that is true, but when the case rate is low this is not a common problem. The ideal size of the grid is adjusted to expected case rate. If you get ambiguity then you just move those samples across to a new grid (in locations that won’t be ambiguous) and test again.
  • nroets 7y ago
    Has anyone used it to better estimate size of the infected population, like a statistical binary search combined with random sampling ? Here in South Africa, we are really unsure if our lockdown is having the a meaningful effect.
• meroes 7y ago
  There's multiple people here suggesting everyday people spread a possibly less lethal strain, in ways that will likely spread every other contagious disease they also had. I think this post needs to be removed now
• socialist 7y ago
  At the end we'll all figure out "immunity" is the best defense. Miracles only happen when common sense takes over.
• IdoRA 7y ago
  A naturally attenuated strain would still be regulated. In the US, 21 USC §321(g): > (1) The term "drug" means… (B) articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; CBER would be the responsible center for the FDA. Other countries have analogous regulations. Could you come to market with a naturally attenuated strain? Yes. Would it take less time? Not really, because you don’t get to do an “end run around the regulations” as you put it in another comment. The logistics of making sure it works and then setting up the supply chain and quality systems are what take the most time. There are no shortcuts in medicine.
  • exikyut 7y ago
    Alternatively, if this approach actually works, all the countries in the world that can appropriately adapt their regulations will survive, and the ones that choose not to won't. Natural selection versus bureaucracy!
    • asdfasgasdgasdg 7y ago
      It's the "figure out if it actually works" part that is going to take most of the time for any potential prophylactic option for COVID-19. The bureaucratic overhead in this particular case is not going to be the inner loop.
  • danieltillett 7y ago
    There are plenty of shortcuts in medicine. Think how you would stop this strain from being spread by individuals once it was identified. This strain will spread no matter what the FDA says. Personally I think the regulatory authorities would rapid approve it based on the epidemiology data collected in the process of finding the strain. The FDA has already shown that it can move faster than its usual glacial pace given sufficient motivation. The much more important question is when are we going to start seriously looking for such a strain?
    • ajross 7y ago
      Serious question: are we not? People are sequencing these things like crazy (c.f. the nextstrain.org data). Epidemiologists are working like mad to come up with data on severity in regions all over the globe. Virologists everywhere are dropping what they're doing otherwise to work on covid. It sorta strains reason to argue that none of these people thought of looking for an attenuated strain. Isn't the simpler truth just that finding one takes a lot of ground work that's already being done, but hasn't born fruit yet?
• JohnJamesRambo 7y ago
  I like your idea a lot. It seems that a 12 nucleotide insertion mutation is responsible for a lot of the Covid-19 virulence. If such a large mutation is possible, how would we prevent your loss of function asymptomatic strain from reverting its mutation in the wild? How big of a mutation are you envisioning? Is it impossible for it to be reverted in the wild or just unlikely? https://www.nature.com/articles/s41591-020-0820-9 https://www.nature.com/articles/s41591-020-0820-9
  • danieltillett 7y ago
    I think 12 nucleotides is too small, I would be happier with something north of 30. There have already been strains identified with a deletion of 382 bases [0]. 0. https://www.biorxiv.org/content/10.1101/2020.03.11.987222v1.full.pdf https://www.biorxiv.org/content/10.1101/2020.03.11.987222v1....
• Tarrosion 7y ago
  Any thought of writing a WaPo, NYT, etc. editorial? With an idea this potentially impactful and your credentials, seems like you'd have a good shot of being accepted.
  • omosubi 7y ago
    Is that where decision makers are looking right now? I don't ask this to be snarky, but it seems that they post so many op-eds that it would get buried
  • danieltillett 7y ago
    I suspect more of the people who I want to expose the idea to have seen it here on HN.
• m348e912 7y ago
  I'm late to the comment party but I wanted to say our hope might just be better treatment (and not a vaccine). Covid-19 doesn't have to fatal as long as hospitals _don't_ use their standard protocol. Here's what I mean: https://www.evms.edu/media/evms_public/departments/internal_medicine/EVMS_Critical_Care_COVID-19_Protocol.pdf https://www.evms.edu/media/evms_public/departments/internal_...
  • danieltillett 7y ago
    There is a large percentage of the world’s population that can’t access any hospital, let alone get treatment.
    • m348e912 7y ago
      Does this treatment you can't get include vaccinations? I'm not sure what you're getting at. Anyway, hydroxychloroquine is on the list of World Health Organization Model List of Essential Medicines.[0] It's a widely available drug that can be found even in remote parts of Africa and India where malaria is prevalent. [0]https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-...
• Robotbeat 7y ago
  This is the same thing as a vaccine (but without doing the safety due diligence). IMHO as a not-medical-professional, we’d be better off with just using one of the (dead) vaccine candidates early than with a slightly attenuated live virus. We actually started clinical trials of the Moderna mRNA vaccine in humans a month ago. We may have some early safety data. Better that than intentionally exposing people.
  • danieltillett 7y ago
    No it is not. There is still safety data, it has just been done by nature and not by jabbing people in the arm with some experimental vaccine.
    • Robotbeat 7y ago
      No, the safety data is not well controlled in this case. There are lots of ways to administer a vaccine, it doesn't have to be injection. Look up the history of vaccination. Starting in the late 18th Century, people used to do this exact thing for early vaccinations: they found a naturally occurring, less pathogenic strain (for instance, cowpox[1] in the days of smallpox), and intentionally exposed people. This is exactly the same thing as a vaccine except less controlled and, ultimately, much less safe. . [1]The root of "vaccine" is "vacca," i.e. Latin for "cow," for this reason.
      • danieltillett 7y ago
        Safety data can be gained from epidemiology studies. There is more than one way to work out if a treatment is safe and effective.
        • Robotbeat 7y ago
          Epidemiological studies are much poorer than clinical trials. I’d rather have low-N but well controlled clinical trials than nebulous epidemiological studies.
• czep 7y ago
  Finding an attenuated strain that spreads as easily but is less deadly does sound like our best hope. Such a strain would "crowd out" the deadly strain, effectively blocking it from causing harm. If life was a Star Trek episode, Picard would be saying "Make it so" right about now.
  • TeMPOraL 7y ago
    "Captain's log, stardate 73740.9. The Enterprise has taken on board a distinguished Federation virologist, dr. Daniel Tillett, to help him with his search for a less harmful strain of the virus that's currently ravaging several planets in Federation space. The doctor is confident that such an attenuated strain could be used to swiftly end the ongoing pandemic." I would watch that episode. Hell, I'd watch any new episode; unfortunately, the only proper Star Trek we've had since Enterprise stopped airing is The Orville.
    • throwanem 7y ago
      And then it turns out similar to "Ethics", where the virologist's work is questionably founded and potentially quite dangerous, we get a Picard speech about how sacrificing some to save others is wrong, Data and Crusher technobabble up a treatment that doubles as a vaccine, the photogenic kid gets saved at the bottom of the fourth act, Admiral Nechayev and Picard fence a bit, credits. Pretty wild to count Enterprise as "real Trek", but not Discovery. And hey, TNG was seminal and I loved it growing up too, but let's be real, it's showing its age quite badly these days.
      • TeMPOraL 7y ago
        > And then it turns out similar to "Ethics" Perhaps, but that's Star Trek. It wasn't always obvious how the episode would end. > Pretty wild to count Enterprise as "real Trek", but not Discovery. Why? TNG, DS9, VOY and ENT, together with movies from TMP to NEM, form a certain coherent whole - both artistically, with themes, styles, pacing, and story-wise with a shared universe. Both Discovery and Picard, as well as JJ's movies, depart from that significantly. The style is different, the pacing is different, the stories and ethics are different (arguably much more shallow). The Orville, though it was meant as a TNG-era Star Trek parody, seems much closer in pacing, style and ethics to that core TNG-era trek than Discovery. > TNG was seminal and I loved it growing up too, but let's be real, it's showing its age quite badly these days How so? Remastered version holds up pretty well today, I'd say.
• Geenkaas 7y ago
  The Netherlands is testing with plasma from a recovered patient right now: Source: https://nos.nl/artikel/2330036-nederlandse-coronapatient-heeft-plasma-met-antistoffen-ontvangen.html https://nos.nl/artikel/2330036-nederlandse-coronapatient-hee... NB: I am NOT a microbiologist and do not know how far this is related.
  • badfrog 7y ago
    Here's some info on that from US FDA: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma https://www.fda.gov/vaccines-blood-biologics/investigational...
  • shiftpgdn 7y ago
    I am in an open source Christmas lights community that sources pixels from China. About a month and a half ago one of the Chinese vendors posted that the PRC is full steam ahead on Plasma therapy. He also stated his elderly father had gotten covid and was recovered within 24 hours. It seems very promising.
  • maxerickson 7y ago
    It's not particularly related. Plasma contains molecules that contribute to immunity. The donation transfers those molecules from the donor to the recipient. It doesn't directly confer any immunity to the recipient, it reduces the amount of virus circulating in their body, giving their own immune system more time to respond.
• carlob 7y ago
  I see one potential drawback to this (as opposed to a vaccine), and that is the impossibility to protect immunodeficient subjects: if you have an effective vaccine you can be fairly certain that people with leukemia or full blown AIDS can be protected by herd immunity when surrounded by people who have been vaccinated. In this case it's not clear to me whether this would work. I have to say I'm no virologist, but I find the fact that this milder strain can still propagate on its own some kind of a double edged sword. Maybe someone who knows more about this than I do could comment.
  • jseliger 7y ago
    Right now it is also impossible to protect immunodeficient subjects, but herd immunity could help. I don't think the author ever says, "We should do this and only this in lieu of a vaccine." The argument is, "This can be done now, or soon, while a vaccine will take 12 - 18 months, if not longer."
    • carlob 7y ago
      It's not quite the same ethically: for all of this to work you should make this attenuated virus spread faster than the more deadly ones, so there is a positive act to be made which goes directly against the Hippocratic oath (do no harm). Immunodepressed subjects right now are protected by isolation and by the fact that right now a smallish percentage of the general population is an asymptomatic carrier, if we were to start spreading this actively those variables would change.
• nickthemagicman 7y ago
  "We have a choice of taking some small risk now, or face the certainty of a much worse problem later. Time to accept some risk and do something." Agreed 100%. What about simply letting the people who young and healthy or immune go about their lives? Letting the young and healthy get sick and then become immune is essentially using an attenuated human instead of an attenuated virus. Same outcome though. This would both build herd immunity and keep the economy going.
  • garethrowlands 7y ago
    This was the UK government's plan until they realised just how many people would die as a result.
    • nickthemagicman 7y ago
      Thats false. The UK's plan was to not quarantine ANYone. The young are basically immune to this. I'm saying quarantine the vulnerable populations and let the healthy populations out.
      • CathedralBorrow 7y ago
        Just before I get into discussing this idea, I'm curious how sure you are about it. The way you describe it it's pretty much a simple solution that just needs implementing. How do you know exactly what the outcome would be?
        • nickthemagicman 7y ago
          From millions of data points it's shown unless you're older or vulnerable you have extremely minimal chance of dying. Then the herd immunity would be build or close to it. It's a much better solution than what we have now that simultaneously killing the economy and human rights.
        • nickthemagicman 7y ago
          Sweden has no quarantine and has been averaging around 400 to 500 new cases daily while UK quarantined everyone and has 4000 to 5000 new cases daily. The interesting thing is that the UK has 60 million people while Sweden has 10 million people. So according to those numbers...how effective is quarantine?
• sharken 7y ago
  It is commendable to search for solutions to the Corona virus. But the author is doing himself a disservice by saying that tens of millions of people worldwide will die. And why is it a bad thing to have to be vaccinated on a yearly basis, poor African countries have not been hit hard that is a fact. The areas being hit the hardest can afford to be vaccinated yearly and is accustomed to it with the yearly flu shot. Other than that, keep up the good work !
  • banachtarski 7y ago
    You’re ignoring the fact that this virus Is an order of magnitude more lethal than the flu, and I would guess that most individuals in poorer countries skip the vaccine altogether.
    • sharken 7y ago
      It has only been proven lethal for very old and people with chronic illnesses. Those people should stay at home and practice distancing.
      • CathedralBorrow 7y ago
        Are you just igoring news that fly in the face of what you're stating here? Have you looked at the current state of NYC?
        • sharken 7y ago
          My wording could be better I admit and yes I have looked at the NYC numbers that show 86% of deaths are due to underlying illnesses, source: https://eu.usatoday.com/story/news/health/2020/04/07/new-york-coronavirus-deaths-data-shows-most-had-underlying-illnesses/2960151001/ https://eu.usatoday.com/story/news/health/2020/04/07/new-yor... Being old and having underlying illnesses is by far the biggest reason for deaths in NYC, with Hypertension and Diabetes being among the top risk factors. Worryingly, in Sweden in the capital Stockholm, around 15% of the staff caring for the elderly have had Corona virus.
• snowwrestler 7y ago
  The idea that naturally mild strain of the coronavirus would provide a durable benefit, but a human-created vaccine would not, seems to me like an idea that needs a lot more explanation. The mechanism of immunity should be the same between those two.
  • perlgeek 7y ago
    The main argument here is that finding a mild strain (and having it tested implicitly by virtue of it infecting many humans) could be faster than developing a human-created vaccine. I don't have any credentials in this field, but IMHO we should attack the problem from all possible angles, including the search for a natural, less harmful strain.
    • snowwrestler 7y ago
      He says: > Apart from the time it will take to develop, trial, and mass produce a vaccine (12-18 months), it is unlikely that any vaccine will be practicable. The reason why is immunity to respiratory viruses (like corona) doesn’t last long – 6 months to 2 years. We would have to keep vaccinating everyone in the world every year (or maybe every 6 months if we are unlucky). This just isn’t going to work in the real world (especially poor countries) and is one of the reasons we don’t have a vaccine for the coronavirus strains that cause the common cold. Unless we can drive the current dangerous SARS-CoV-2 strains to extinction we are going to have a problem with this disease indefinitely. Every one of these objections also applies to a less harmful strain. For example, one reason vaccines don't confer durable immunity to many respiratory infections is because the infectious agents change over time, migrating away from the vaccine response. Well, by the same token, a less deadly strain of such an infectious agent would also change over time at the same rate. On the other hand if we think a naturally occurring strain would provide stable immunity over a long time, then a human-created vaccine would also be stable for a long time. There is nothing magical about naturally occurring strains. They work in the body exactly the same way vaccines do. (Which is of course why vaccines work in the first place.)
      • danieltillett 7y ago
• credit_guy 7y ago
  > "Can’t we just wait for a vaccine? > "No. Apart from the time it will take to develop, trial, and mass produce a vaccine (12-18 months), it is unlikely that any vaccine will be practicable. The reason why is immunity to respiratory viruses (like corona) doesn’t last long – 6 months to 2 years. We would have to keep vaccinating everyone in the world every year (or maybe every 6 months if we are unlucky). " I am not sure I agree with this. I am taking the annual flu shot, along with all the members of my family. I would be fine with an annual, or semiannual, coronavirus shot.
  • aliased 7y ago
    Poor countries can't afford that.
• z3t4 7y ago
  So we need a DIY genome sequence kit. Where can I find a practical guide? What do I need?
  • danieltillett 7y ago
    No we just need the samples and use the instruments we already have. Sequencing the viruses genome is not a complex problem technically.
• annoyingnoob 7y ago
  How do we know that a less deadly strain actually provides some immunity to a more deadly strain? That seems like an assumption here.
  • Amygaz 7y ago
    His assumption is based on live-attenuated vaccines. The measles vaccine being one of those. All the early vaccines where like that. The process only requires heat inactivation. So you end up with a dead or almost dead virus, which can't replicate anymore. Your immune system recognizes it as a foreign agent, makes antibodies to tag it for removal. Today we prefer to immunize with a part of the virus structure, which end up doing the same thing.
    • annoyingnoob 7y ago
      Still seems like an assumption until its tested/proven. I'd prefer a more evidence based approach, evidence from this virus.
      • danieltillett 7y ago
        You can only get evidence if you go out and collect the evidence. I am proposing a way we can actually collect this evidence. Saying something won’t work because there is no evidence when you haven’t look for any evidence is not very logical.
        • annoyingnoob 7y ago
          Just questioning assumptions, in a healthy skepticism kind of way. I have no expertise here. There is a lot of speculation and general fud surrounding covid-19, seems right to question potential 'solutions' when we are light on facts. To be clear, I never said it wouldn't work, I'm saying that it looks like you assume it will work.
          • danieltillett 7y ago
• remote_phone 7y ago
  This entire article is a waste of time from the beginning. The “two strain” theory was debunked the very next day as bad science. http://virological.org/t/response-to-on-the-origin-and-continuing-evolution-of-sars-cov-2/418 http://virological.org/t/response-to-on-the-origin-and-conti... I can’t believe that a month later, this bad science is still being circulated, by a purported PhD and former professor.
  • Amygaz 7y ago
    Thanks for saying that. It is super flawed. I was planning to go through all of his replies to other posters and debunk them one-by-one.
    • sah2ed 7y ago
      > I was planning to go through all of his replies to other posters and debunk them one-by-one. If you disagree strongly with someone, there are much better tools you can use like the down-vote button. Down-voted posts are harder to read and especially bad contributions get collapsed out of view. Going out of your way to hound someone would only lower the S/N ratio here, which is not why we are all here; intellectual curiosity is why we keep coming back here not witch hunts.
  • exhilaration 7y ago
    I'm confused, the paper that's being debunked in your link: https://academic.oup.com/nsr/advance-article/doi/10.1093/nsr/nwaa036/5775463 https://academic.oup.com/nsr/advance-article/doi/10.1093/nsr... Is not the same paper he's pointing to as having found a milder strain: https://www.medrxiv.org/content/10.1101/2020.03.10.20033944v2 https://www.medrxiv.org/content/10.1101/2020.03.10.20033944v... What am I missing? Are they both based on a flawed understanding?
    • brownbat 7y ago
      Not exactly, but the rebuttal includes: "As of 2nd March 2020, there are 111 nonsynonymous mutations that have been identified in the outbreak, these have been catalogued here in the CoV-GLUE resource 504 and can be visualised in Figure 1. At current, there is no evidence that any of these 111 mutations have any significance in a functional context of within-host infections or transmission rates." The premise that there is an "asymptomatic strain" is still theoretically possible but unsubstantiated, despite ongoing investigation. > "I can’t believe that a month later, this bad science is still being circulated, by a purported PhD and former professor. " That strikes me as a bit harsh, given that the posted article doesn't actually rely on two-strain to make its case, just the idea of functional variants possibly being out there somewhere. MacLean's rebuttal didn't definitely exclude the possibility that there's some functional variants out there somewhere, we just don't know, haven't seen it in anything we've catalogued so far. Science is often about calibration. I wouldn't say a search for functional variants is completely worthless. That's why researchers continue to look at variants. On the other hand, completely agree it's overselling to pitch this as a silver bullet for the whole crisis though. Research can be important even when it doesn't solve for everything.
• xvilka 7y ago
  In one of the article comments there is an interesting suggestion on reviving the research on DRACO[1]: > In cell culture, DRACO was reported to have broad-spectrum efficacy against many infectious viruses, including dengue flavivirus, Amapari, and Tacaribe arenavirus, Guama bunyavirus, H1N1 influenza, and rhinovirus, and was additionally found effective against influenza in vivo in weanling mice. It was reported to induce rapid apoptosis selectively in virus-infected mammalian cells while leaving uninfected cells unharmed. They even had a crowdfunding campaign on Indiegogo[2] but as usual, nobody cares about infectious diseases until the pandemic... Now the crowdfunding seems moved to another page[3] [1] https://en.wikipedia.org/wiki/DRACO https://en.wikipedia.org/wiki/DRACO [2] https://www.indiegogo.com/projects/1641241 https://www.indiegogo.com/projects/1641241 [3] https://riderinstitute.org/discovery/ https://riderinstitute.org/discovery/
  • enchiridion 7y ago
    Why did they choose indiegogo over traditional medical research funding?
    • xvilka 7y ago
      Good question. I am even surprised why not Kickstarter - it's more suitable for the larger goals.
      • rzzzt 7y ago
        Flexible funding allows one to keep the proceeds even if the goal is not met in the allotted time. Kickstarter offers only an all-or-nothing payout for projects (unless something changed the last time I checked).
    • X6S1x6Okd1st 7y ago
      The source that wikipedia cites says the following: "However, research on DRACOs has entered the well-known “Valley of Death” in which a lack of funding prevents DRACOs, and many other promising new drugs, from being developed and advancing toward human medical trials. To progress DRACOs research it needs to be demonstrated against clinically relevant viruses (i.e; HSV). To that end an IndieGoGo campaign (http://igg.me/at/EndTheVirus http://igg.me/at/EndTheVirus) was started on October 13, 2015." They don't seem to elaborate on what the hell they mean by the valley of death. http://www.prweb.com/releases/2015/10/prweb13018147.htm http://www.prweb.com/releases/2015/10/prweb13018147.htm
• deleted 7y ago
  [deleted]
• jl2718 7y ago
  This will happen naturally. No need for intervention. The longer it goes the better.
  • danieltillett 7y ago
    This is true, but it might take a few hundred years. I think it would be better if we try and help the process along.
    • jl2718 7y ago
      I'm not sure, but you might be greatly underestimating the rate of evolution for these virii. Generally it is ~10^9 faster than eukaryote evolution (https://viralzone.expasy.org/4136 https://viralzone.expasy.org/4136) and there are many (10^?) generations that occur in every host. Early selective pressure for fast replication makes it deadly, but late-stage selective pressure is to be transmissible through mild symptoms. The end game is that it becomes part of our DNA. I might also mention that the virus doesn't really care about us. Mostly it's interested in infecting our bacteria. That's kind of a joke, but in reality, it says everything about how to control it.
      • danieltillett 7y ago
        We have a pretty good idea how fast corona virus evolve. Yes there will be selection pressure for it to become less deadly, but this can take a long time. My proposal is how we can speed up this process.
• edw519 7y ago
  This reminds me of a story 20 years ago when Pittsburgh Steelers (American football) announcer Myron Cope ran into head coach Bill Cowher... Myron said, "I see that Lee Flowers is playing today after a high ankle sprain 2 weeks ago. But I thought that high ankle sprains took 4 weeks to heal. What gives?" Coach Cowher replied, "4 weeks is true, Myron, for the first high ankle sprain. But if you recall, Lee had a high ankle sprain on the same foot last year. And since subsequent high ankle sprains only take 2 weeks to heal, he's ready to play." Myron paused and asked, "Then why don't you just take the whole team out in February and sprain all their ankles?" (We laughed 20 years ago. Nobody's laughing today.)
  • toyg 7y ago
    I understand the metaphor you’re using, but for the sake of clarity I feel compelled to explain that there is a big difference: ankle-spraining significantly increases in likelihood with each subsequent instance. So “spraining ‘em all” even once would literally result in long-term degradation and increased frequency of injury. They would take less to heal, but would also get injured so often that the aggregated result would be worse than before. Sadly joints tend to work a bit differently from the immune system (with some exceptions).
  • pjc50 7y ago
    This reminds me of the old joke that, because the possibility of there being two bombs on a plane is infinitesimally small, you should always bring your own bomb with you.
• aazaa 7y ago
  > Aren’t most people who have mild/asymptomatic cases infected with a dangerous strain? > Yes. Almost all (>99.9%) of people who are infected (and have a mild case) are infected with a dangerous strain of the virus, they just happen to have an immune system that can control the virus well. With COVID-19 a mild case does not mean you are infected with an attenuated strain – for most people with a mild case if they happen to infect a person with preexisting conditions or who is old, that person will be at a high risk of dying. A mild case does not equal a harmless strain. Even if the weak-strain hypothesis holds water (which remains to be seen), the proposal is predicated on something that's physically impossible to do. Test large numbers of people. Hundreds of millions or even billions. Then, given those tests, find the weak strains. That's also the minimum needed to "re-open" the country. If we could test 20-30% of the population, we'd be in great shape. But we can't and may not ever be able to. Even if you can test that many, you've got to prove that the weak strain is harmless. Then you've got to figure out how to administer doses safely. So the solution must work within those parameters. And the only practical option is a vaccine. > The major risk is the virus we think is safe is not 100% safe. While we can use community spread of the identified strain to estimate how safe it will be (i.e. if it has infected 1000 people and none have got seriously ill then we should have a pretty good idea that it is safe), but our knowledge will be incomplete. We can of course spend the next few years testing and trialling, but if we do this by the time any strain is shown to be 99.999% safe (not even the polio vaccine is 100% safe) we will have all got COVID-19 and the world’s economy will be a smoking ruin. This guy is absolutely bonkers, or pulling a Swift. He's proposing the (forced?) infection of a large portion of the population with a live virus that has been through none of the safety protocols established over many decades of catastrophic failures. This is not how drug testing works. This is not how public health works. This is not how you assess safety. This is not ethical. This is tech bro medicine at its absolute worst.
• Glavnokoman 7y ago
  I totally missed it from the article but how is he going to tell the deadly strain from the less deadly one? I mean I understand how they can tell the difference between the two strains. But how to tell that some particular strain is less deadly? To the best of my understanding the only way to get there is to sequence the virus from statistically significant number (~10^5 ??) of carriers including the significant proportion of those with asymptomatic cases. Not realistic IMHO.
  • joncrane 7y ago
    Not to mention relying on each person's account of the severity of the symptoms, and coding that into a dataset that corresponds to the sequencing results. You need a LOT of asymptomatic people with the strain in order to draw any strong conclusions. The upside is, you may draw other very interesting conclusions while collecting data for this mission, and be able to "pivot" if you will.
  • danieltillett 7y ago
    This is all described in the post. I have updated it to make it a little clearer (based on feedback). If you missed it the first time around you might get it now.
• bluefox 7y ago
  Perhaps a first step is to simulate a population where several variations of the virus exist, and where people set out to get infected by those who are believed to host a "safe" variation. What is the likelihood that interaction between the variations and people's mistaken beliefs screw this up?
• ekianjo 7y ago
  > Singapore and Japan have recently seen this in action where they eased restrictions and found the disease came back and they had to reintroduce restrictions. Poorly informed, Japan did not even have restrictions in the first place.
  • danieltillett 7y ago
    Yes they did, just not the same as everyone else.
    • ekianjo 7y ago
      Closing schools and doing nothing else does not count much in terms of restrictions.
• brownbat 7y ago
  I posted and deleted a few comments. I don't know what to make of this and it's getting controversial. If it could be helpful, I'd love to improve it. I just don't know where it fits in ongoing discussions by prominent researchers on analysis of strains and types. Three things that jump out at me: a) You'll get more credibility from having a thorough lit review than from listing credentials. Linking to magazine articles from journalists on genetic variations, when there's academic research to cite, is a little bewildering. b) You don't identify something harmless by just testing asymptomatics. This is counterintuitive, but a great example of the Wason selection task: https://en.wikipedia.org/wiki/Wason_selection_task https://en.wikipedia.org/wiki/Wason_selection_task You would probably want to survey the rate of variants in asymptomatics in a certain community, then compare that with the rate of variants in fatal cases in the same community to look for significant differences (and be fully prepared not to find any significant differences beyond chance, a real and likely possibility). c) I'm still not sure what the author is specifically recommending we do next. Researchers are looking for functional variants, we don't have one to distribute yet, so we should do more sequencing. Ok, great. From what populations? How many geographic areas? Where do we get the samples? There are bottlenecks in sample collection, how do we overcome those? Given (b), how can we get more samples from fatal cases, to compare virulence to those in the general population? Task overloaded hospitals to send us additional samples from dying patients? Is there another way we can get this info? I don't want to dismiss this out of hand, this might be a good area for additional focused research. I do think there are some key unanswered questions though, and currently a worrying disconnect with the current state of research on variants. EDIT: Daniel, I know you're going through the comments here, and some of them have gotten pretty harsh, sorry for that. I genuinely hope you're on to something, and are able to continue to refine the post into a more robust and specific proposal using all this feedback, despite the tenor of some of the comments. That's really the best case for all of us, so good luck.
  • ubercow13 7y ago
    Do you know what the commonly guessed incorrect solution to that card problem supposed to be?
    • 7y ago
• projektfu 7y ago
  Isn’t such a mutation just one SNP away from returning to virulence?
  • pacaro 7y ago
    No. TFA makes clear that they are not looking for a SNP, but rather a deletion. In a comment further up, they suggest a deletion on the order of several hundred base pairs
• ineedasername 7y ago
  I'm always skeptical simple solutions proposed to solve complex problems. Unintended consequences or unanticipated roadblocks are often an issue. In this case, the author might under estimate the logistics involved in getting this done. At a minimum, the author does not adequately address the logistical challenges of this endeavor in the context of already challenging testing environments. The "quick & cheap" aspect of this is therefore a claim without support. It might be a promising line of endeavor, and we should pursue multiple parallel initiatives, but the resources needed to pursue this are highly correlated with the resources needed to perform many of the other initiatives that are also promising. There is a bottleneck. Why should this take precedence over other already promising lines of inquiry?
  • the-pigeon 7y ago
    I don't think this is a very simple solution at all. It's really just a different vaccine approach and this isn't the first person to suggest it. It's been talked about online since February if not before. Not to say I don't think it's a viable idea and I do think it needs more visibility. As the author states this has worked for other diseases.
    • ineedasername 7y ago
      The author proposes it as "quick & cheap" and leaves out nearly all logistical considerations. To my thinking, that is an overly-simple proposal.
      • danieltillett 7y ago
        Something can be quick and cheap without being easy. The proposal is far from easy. The post leaves out a lot of technical details that the average non-scientist doesn’t need to know.
• aliased 7y ago
  Very interesting post. One way to get this talked about more widely is to somehow get it in front of Trump.
• ineedasername 7y ago
  The author doesn't address how widespread the testing would need to be to accomplish this. What sample size is needed? Does it need to be geographically diverse? Does the human population tested need to be genetically diverse? Also: Why is this faster than other methods of vaccine development already underway? Once developed, wide-scale manufacture & deployment is an enormous logistical challenge completely separate from R&D. Can this use existing vaccine manufacture & distribution channels? It's difficult to really assess the viability of this plan without it taking into account many of these details. To my moderately-informed-outsider thinking (which lets face it, is the crowd the author was targeting by posting here on HN) it may suffer from the "ideas are easy, execution is hard" problem, because execution details apart from the actual R&D side are lacking. I'd like to hear more from the author on the topic though.
  • danieltillett 7y ago
    I actually do address the numbers needed in the post. Yes you would want to sample as widely as possible in the ideal world, but more important is just getting the right samples. The reason why this would be faster is the process of looking for the strain and identifying it as safe would generate data that would allow the regulatory authorities to approve its use. Manufacturing would not be the limiting factor here.
    • ineedasername 7y ago
      I read the whole article through. Now I have done so twice. Maybe I have a blind spot, maybe I misunderstand something, but I don't see where you address the number of tests needed. Certainly you don't address the need (or lack thereof) for geographically & genetically diverse testing. Your background also does not appear to contain detailed experience within the manufacturing and deployment side of vaccines, so I hope you'll forgive me if your lack detail on that end isn't mitigated by simply saying "Manufacturing would not be the limiting factor here" without further explanation. You say you'd like to get this proposal in front of influential people, but why would Bill Gates assume the logistics are fine, not a problem, without you specifically addressing the issue? And if I can't get answers to the questions I've raised after 1 full reading, one slightly faster reading, and an exchange with the author himself, then if I were a person of any influence I would not devote limited time to this proposal. Presumably you posted here to get such attention. Presumably you would engage a bit more and answer in greater detail if you knew I were someone who could help advance this in some way. (I'm not-- I have access to researchers in academe but no influence) But I don't see you getting the attention needed, not without a proposal that moves beyond the R&D phase in significant detail Personally I find the lack of logistical details beyond the R&D and sequencing side of things indicate that your own business interests have you focusing on that end of the project to the detriment of other factors that need to be taken into consideration. Please note that I'm not saying you're doing this for the money: Only that your current area of professional endeavor is the area of the problem where you have focused your proposal, and the areas where it's lacking are not bolstered by your simple assertion of "they are are not a problem." You have posted to an audience that is not automatically going to know how your R&D could be logistically deployed, but also an audience that knows ideas are easy, and execution is hard. If you wish to have your proposal widely accepted here, if you wish people here with connections to those who could influence anything, these are things you need to address.
• ck2 7y ago
  This is why scientists and mathematicians never make it as politicians in the USA You may have the best idea in the world, but your presentation is terrible, the rambling is terrible, the assumption you are the only person to think of this is terrible and the urge to get the attention of someone important to pay for it is terrible. The sad truth is you need to fit your idea into the size of a tweet, write the long version elsewhere linked. If you can't do that, someone else can and will and their idea will win over yours because you can't get attention rambling like that And governments are never going to purposely infect their populations, if you think anti-vaxers are bad, imagine when people in the USA have the choice not to get the injection, 99% of the fox news viewers will refuse and the president will say "well you can if you want but I won't" (I mean he won't even stop shaking hands or wear a mask)
  • danieltillett 7y ago
    You are welcome to rewrite my post and even claim the idea as your own if you want. Make it as short as a tweet (which I have done by the way) and send it out into the world.
• david_w 7y ago
  He leaves out "developing a treatment" as an option. Why?
  • danieltillett 7y ago
    Because it is a discussion about another topic and I wanted to keep the post short. Treatments are good, but this will not solve the problem.
• rediguanayum 7y ago
  (caveat: amateur) I think this is a great idea to get community involvement upon. I'm sure you know there's a network of researchers on Twitter (I'm aware of the one centered around the Krogan lab in UCSF i.e. @KroganLab), and on Reddit (reddit.com/r/covid19) that have been posting ideas back and forth. Consider posting there. I like your idea because it circumvents a number of ethical issues, but may be time/resource consuming. Another approach but one that quickly hits those ethical issues during testing would be to knockout immunosuppressant genes as popularly described by: https://www.nytimes.com/interactive/2020/04/03/science/coronavirus-genome-bad-news-wrapped-in-protein.html https://www.nytimes.com/interactive/2020/04/03/science/coron... (preprint https://www.biorxiv.org/content/10.1101/2020.03.22.002386v3.full.pdf+html https://www.biorxiv.org/content/10.1101/2020.03.22.002386v3....). Perhaps mice model? An in between approach that might be better, would be to target your search by looking for changes that likely inactivates the immunosuppressant genes. I and I'm sure many others dearly hope your approach works. Godspeed sir.
• chaseadam17 7y ago
  I am not an expert, so I apologize if these are a dumb questions, but here goes: 1) Wouldn't natural selection result in a milder strain crowding out a more deadly strain? After shelter in place lifts, people with a mild strain will be more likely to go out and spread the virus whereas people with the deadly strain will be more likely to stay home sick. 2) Is there any consensus on whether we become immune to COVID after getting it (e.g. if we get a mild strain will we really be immune to a deadly one)? I've heard different opinions and I'm wondering what the leading hypothesis is at the moment. Thanks!
  • bob33212 7y ago
    That sounds correct, but "scientifically" we have to spend million of dollars and months of time to say for sure.
• lucas_membrane 7y ago
  >> The polio, ... vaccines are all live attenuated viruses. IIRC, the USA came very close to eliminating polio by switching between live virus vaccines and killed-virus vaccines several times.
• torbjorn 7y ago
  I sent this article to a vaccine researcher I know, here are his comments (I have his permission to share this): TLDR the virus mutates too quickly for this to be safe. " There are many ways to make vaccines, and the oldest one is to take the wild-type pathogen, and either ‘break’ it (‘attenuate it’), or find an example in nature that’s messed up and can’t cause disease. The initial smallpox vaccine was cowpox: Close enough to human smallpox that it elicited protective immune responses, but too maladapted to humans that it couldn’t thrive in us, and would be caught by the slow-walking cops of our immune system. The strategy used for many of the 1950s/60s-era vaccines was to isolate the disease-causing pathogen, then in a laboratory force it to grow in progressively more-messed-up circumstances. This would drive evolution of the pathogen to mis-adapted freaks. For example, the mumps isolate was from the daughter of the Merck scientist (Maurice Hilleman), and he grew it in cow cells, then lizard cells, then insect cells (or somesuch, I don’t know exactly). By the end of the process, the thing could still infect humans, but just BARELY. Nowadays, with molecular biology, we can rationally design the ‘attenuations’, and do knock-outs or modifications. Which brings me to low-virulence wildtype isolates of SARS-CoV-2 (S2): The root problem here, as with HIV, is it’s a super-fast-evolving RNA virus. Sure, a particular isolate might be low-virulence NOW, but give it a few weeks on a cruise ship and – viola! – nasty bugger ahoy! When SARS-CoV-1 broke out, years back, it had a high lethality and freaked out the public health experts at the time (in fact, we were writing proposals to get into the research, but then it got contained). At that time, efforts were initiated to make a vaccine, based on the observation that all that was needed with the Bcell production of ‘neutralizing antibodies’. This is the long standard, matching most existing vaccines. So it was a low-weight lift, for vaccine developers (relatively easy-peasy). The project got pretty far along, but then stopped when SARS-CoV-1 disappeared as a threat. When MERS, then SARS-CoV-2 came along, they resurrected the previous, promising design, based on a slow-evolving vector. But in the case of S2, they discovered that the targeting receptor usage of S2 was significantly different, so the design required a significant re-tune. Even so, the Chinese (I think) did it, injected the first people several weeks back, and I don’t think it works well (too early for formal reports). S2 is nasty, as HIV is. It is using evolution against us. And because its hypermutable (like the influenza viruses), it’s going to be nearly impossible to make one vaccine that works cycle after cycle. It will continue to evolve, but the subsequent cycles will probably have lower lethality than this first pass (which was completely novel to the human immune system, so we had no ‘herd immunity’ protection). Going forward, it will be hard for highly-virulent forms to transmit if they kill their hosts too quickly, which will select for less-virulent forms. The trick is to stay alive during this pass. The only mechanism we have to do this is to not get infected. The only way to do that is to not expose ourselves to infected people, or the things they’ve touched. We’re back to how things were in the 1800s. Better than no science, but about the same as post-epidemiology/cell-theory-of-disease (1890s) But as I said, this vaccine should be RELATIVELY easy to develop. It doesn’t have to be perfect, it just has to blunt viremia (so that the global pneumonia it causes in your upper/lower respiratory system doesn’t cause aveoloar collapse. In other words, even working a little bit will probably massively lower the death count. But even an easy-peasy vaccine will take 18 months. There’s just no getting around that, unless you want to inoculate 5 billion people with something that might make the pandemic worse."
• stevespang 7y ago
  Why not simply allow the general population to breathe Covid19 virus particles that have been exposed themselves to UVC light in a 2 meter long tube at slow air flow ? I assume that would sterilize the incoming air, while allowing immunity to build.
• beagle3 7y ago
  IIRC this idea is the origin of the word “vaccine” - from vache, French for “cow” - people used to intentionally get infected with cow pox 300 years ago, and it would confer protection against smallpox. On phone so hard to check and link.
• temac 7y ago
  Is there a guarantee it would not associate with other viruses (possibly other strains, or even something worse?) And the lack of testing to "save time" actually does not look like a good idea for a live virus you want to give to the whole earth.
  • ruslan 7y ago
    IMHO, he is not going to give new virus to the whole earth, the virus already exists hence freely speading by itself from host to host. The idea is to speed up spreading of "good" virus to preempt spreading of a bad one and finally make the last to extinct.
• nikolay 7y ago
  I hear a lot of ideas, which ignore the indications from both China and South Korea about re-infection. Nobody for sure knows how long the immunity lasts. Also, people could be asymptomatic/mild-symptom, just because they have a strong immune response, not because the strain is less deadly. How do you quantify who is immunosuppressed and who has a well-functioning immune system?
  • danieltillett 7y ago
    Yes, but this idea of mine is not one of these ideas.
    • nikolay 7y ago
      I read your idea, but it doesn't address the exact points I listed - selecting a "less deadly" strain and having fingers crossed that immunity persists. So far, many have insufficient antibody counts and get reinfected. I just saw a number around 20%.
      • danieltillett 7y ago
        There are lots of things we don’t know right now. This is not a reason for not acting. If my proposal works we don’t need to worry about immunity persisting because the dangerous strains will be driven to extinction.
• tim333 7y ago
  Sounds like a good idea. Another interesting possible solution which can be used now but is a bit unproven is to use hydroxychloroquine + zpak + zinc or some variation on that on people with symptoms or who test positive as it seems to reduce viral spreading. Bit controversial but the results in Marseille look quite good - the infection rate in those tested has roughly halved recently while France as a whole is going up. https://madeinmarseille.net/64805-covid-19-didier-raoult-resultat-chloroquine/ https://madeinmarseille.net/64805-covid-19-didier-raoult-res... https://www.mediterranee-infection.com/covid-19/ https://www.mediterranee-infection.com/covid-19/ And the anecdotal reports from the Zeleko guy are good even if people think he's a nut. Also in the Rome area "every single person with Covid-19 that has early signs, like a cough or a fever for example, is now being treated with the anti-malaria drug." Which may provide data going forward https://www.trustnodes.com/2020/03/29/italy-finally-starts-mass-treatment-with-hydroxychloroquine https://www.trustnodes.com/2020/03/29/italy-finally-starts-m... Anyway unproven but may be a way forward if the results prove good.
• robocat 7y ago
  Another relevant link: https://www.medrxiv.org/content/10.1101/2020.04.14.20060160v1 https://www.medrxiv.org/content/10.1101/2020.04.14.20060160v...
  • robocat 7y ago
    And another about mutation rate being a lot higher than thought: https://www.scmp.com/news/china/science/article/3080771/coronavirus-mutations-affect-deadliness-strains-chinese-study https://www.scmp.com/news/china/science/article/3080771/coro...